Pancreatic adenocarcinoma (PAC) is associated with extremely poor prognosis and remains a lethal malignancy. The main cure for PAC is surgical resection. Further treatment modalities, such as surgery, chemotherapy, radiotherapy and other locoregional therapies provide low survival rates. Currently, many clinical trials seek to assess the efficacy of immunotherapeutic strategies in PAC, including immune checkpoint inhibitors, cancer vaccines, adoptive cell transfer, combinations with other immunotherapeutic agents, chemoradiotherapy or other molecularly targeted agents; however, none of these studies have shown practice changing results. There seems to be a synergistic effect with increased response rates when a combinatorial approach of immunotherapy in conjunction with other modalities is being exploited. In this review, we illustrate the current role of immunotherapy in PAC.

中文翻译：

---

胰腺癌的免疫疗法：2020年更新。

胰腺腺癌（PAC）与极差的预后相关，仍然是致命的恶性肿瘤。PAC的主要治疗方法是手术切除。进一步的治疗方式，例如外科手术，化学疗法，放射疗法和其他局部区域疗法，提供了较低的存活率。当前，许多临床试验试图评估PAC中免疫治疗策略的有效性，包括免疫检查点抑制剂，癌症疫苗，过继性细胞转移，与其他免疫治疗剂，放化疗或其他分子靶向药物的联合治疗；然而，这些研究都没有显示出改变实践的结果。当采用免疫疗法与其他方式相结合的组合方法时，似乎具有增加的响应率的协同效应。在这篇评论中